Aticaprant (Clinically Developed Kappa-Opioid Receptor Antagonist) Combined With Naltrexone Prevents Alcohol “Relapse” Drinking

Alcohol relapse is the treatment target for medications development for alcohol dependence. Aticaprant, a selective and short-acting kappa-opioid receptor (KOR) antagonist, has recently been under development for new clinical implications (depression or anhedonia). Recent studies have also found tha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Y, Zhou, DC, Kreek, MJ
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275124/
https://www.ncbi.nlm.nih.gov/pubmed/35832748
http://dx.doi.org/10.13188/2327-204x.1000032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275124/
https://www.ncbi.nlm.nih.gov/pubmed/35832748
http://dx.doi.org/10.13188/2327-204x.1000032

Ejemplares similares